designed a novel dual-targeting ligand by fusing angiopep-2, which can enhance drug delivery across BTB and BBB to glioma cells by targeting low-density lipoprotein receptor-related protein (LRP), and CD133 aptamer into one unit. Here, PROM1 is linked to glioma.